

RYDAPT NOW SUPPORT PROGRAM

Novartis can help provide the support you need





RYDAPT NOW is a support program for patients taking RYDAPT.

RYDAPT[®] (midostaurin) capsules is a prescription medicine used to treat adults:

- newly diagnosed with a certain type of acute myeloid leukemia (AML), in combination with certain chemotherapy medicines
 - Your health care provider will perform a test to make sure RYDAPT is right for you
- with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL)

RYDAPT is not safe when given to children in combination with chemotherapy. It is not known if RYDAPT is effective in children.

Please see Important Safety Information on the following pages. <u>Click here</u> for full Prescribing Information for RYDAPT.



TABLE OF CONTENTS

RYDAPT NOW —a partner during your journey	3
RYDAPT NOW Free Supply Programs	4
How to enroll in RYDAPT NOW	5
Approved Uses and Important Safety Information	6
Financial support	11



Please see Important Safety Information on the following pages. <u>Click here</u> for full Prescribing Information for RYDAPT[®] (midostaurin) capsules.

RYDAPT NOW— A PARTNER DURING YOUR JOURNEY

With our wide range of resources and support, the RYDAPT Care Coordinators at **RYDAPT NOW** can help you gain access to your medicine.

For both FDA-approved indications for RYDAPT $^{\rm \tiny (midostaurin)}$ capsules, Care Coordinators are there to support you



Assisting you with access to RYDAPT as you transition between inpatient and outpatient settings*



Helping you find a pharmacy based on your insurance plan, and get your medicine according to your plan's guidelines



Offering support with insurance verification to help you understand how to get your medicine and what your financial responsibilities are

- Providing information about prior authorization requirements
- Initiating a benefits investigation in the inpatient setting in preparation for transitioning to the outpatient setting*



Providing information about financial assistance that may be available

*For patients with newly diagnosed FLT3-positive acute myeloid leukemia (FLT3+ AML) only.

Call **1-800-282-7630** or visit **www.RYDAPT-NOW.com** for information on how to enroll in **RYDAPT NOW** and to learn more about the ways we can help.

Novartis cannot guarantee that patients who enroll in **RYDAPT NOW** will be successful in obtaining insurance coverage for treatment or will receive financial assistance.

Please see Important Safety Information on the following pages. <u>Click here</u> for full Prescribing Information for RYDAPT.

RYDAPT NOW FREE SUPPLY PROGRAMS

For appropriate patients with AML: RYDAPT NOW Access Program

If your doctor prescribes RYDAPT[®] (midostaurin) capsules for newly diagnosed FLT3+ AML based on the approved label and there is a delay in your insurance coverage as you transition out of the hospital, you may be eligible to receive a free 14-day supply of RYDAPT shipped directly to your home to avoid disruption in your treatment.

For appropriate patients with any of 3 types of systemic mastocytosis (SM)*: RYDAPT NOW Free Trial

If you are prescribed RYDAPT for advanced SM, you may be eligible to receive a free 28-day supply of RYDAPT shipped directly to your home or another convenient location, allowing you to begin therapy quickly.

No purchase of RYDAPT is required. Novartis cannot guarantee that every patient who enrolls in **RYDAPT NOW** will be successful in obtaining insurance coverage for treatment.

*Includes aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL), collectively referred to as advanced SM.



Visit **www.RYDAPT-NOW.com** for information on how to enroll and to learn more about the ways we can help.



Please see Important Safety Information on the following pages. <u>Click here</u> for full Prescribing Information for RYDAPT.

HOW TO ENROLL IN RYDAPT NOW



Access **RYDAPT NOW** online at **www.RYDAPT-NOW.com** and download the Service Request Form



Complete the Service Request Form with your health care provider and fax it to $\ensuremath{\textbf{1-888-891-4924}}$

OR



Call **1-800-282-7630** from 9 AM to 8 PM ET, Monday through Friday, to begin the enrollment process

Ask about 1-on-1 Nurse Navigators who can help support you on your treatment journey in addition to enrolling in **RYDAPT NOW**.

RYDAPT NOW Care Coordinators are able to provide information in more than **160 languages.**

Please see Important Safety Information on the following pages. <u>Click here</u> for full Prescribing Information for RYDAPT[®] (midostaurin) capsules.



Approved Uses and Important Safety Information

WHAT IS RYDAPT?

RYDAPT[®] (midostaurin) capsules is a prescription medicine used to treat adults:

- newly diagnosed with a certain type of acute myeloid leukemia (AML), in combination with certain chemotherapy medicines
 - Your health care provider will perform a test to make sure RYDAPT is right for you
- with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL)

RYDAPT is not safe when given to children in combination with chemotherapy. It is not known if RYDAPT is effective in children.

WHAT DO I NEED TO KNOW BEFORE AND WHILE I TAKE RYDAPT?

Do not take RYDAPT if you are allergic to midostaurin or any of the ingredients in RYDAPT. See page 10 for a complete list of ingredients in RYDAPT.

• Signs and symptoms of an allergic reaction to RYDAPT have included trouble breathing, flushing, chest pain, throat tightness, and swelling of your lips, mouth, or throat. Get medical help right away if you have any of these signs or symptoms

Click here for full Prescribing Information for RYDAPT.

Before you take RYDAPT[®] (midostaurin) capsules, tell your health care provider about all of your medical conditions, including if you:

- have any lung or breathing problems
- are pregnant or plan to become pregnant. RYDAPT may cause harm to your unborn baby. Tell your health care provider right away if you become pregnant during treatment with RYDAPT or think you may be pregnant

Pregnancy Registry: There is a pregnancy registry that monitors the health of females and their babies exposed to RYDAPT during pregnancy. Females who have taken RYDAPT during pregnancy, or who have been exposed to RYDAPT during pregnancy through a male partner taking RYDAPT, should contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or at https://psi.novartis.com

- If you are able to become pregnant, your health care provider may perform a pregnancy test within 7 days before you start RYDAPT
- Females who are able to become pregnant should use effective birth control (contraception) during treatment with RYDAPT and for at least 4 months after the last dose of RYDAPT
- Males who have female partners that are able to become pregnant should use effective birth control during treatment with RYDAPT and for at least 4 months after the last dose of RYDAPT
- are breastfeeding or plan to breastfeed. It is not known if RYDAPT passes into your breast milk. You should not breastfeed during treatment with RYDAPT and for at least 4 months after the last dose of RYDAPT

Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

<u>Click here</u> for full Prescribing Information for RYDAPT.



Approved Uses and Important Safety Information (cont'd)

HOW SHOULD I TAKE RYDAPT?

- Take RYDAPT[®] (midostaurin) capsules exactly as your health care provider tells you, even if your health care provider's instructions differ from the information in this brochure
- Your health care provider will tell you how many capsules of RYDAPT you need to take. Do not change your dose unless your health care provider tells you to
- Your health care provider will prescribe medicines to help prevent the nausea and vomiting during treatment with RYDAPT
- Take RYDAPT 2 times a day (about every 12 hours apart)
- Take RYDAPT with food
- Do not open or crush RYDAPT capsules
- If you miss a dose of RYDAPT, take your next dose at your scheduled time. Do not take an extra dose to make up for a missed dose
- If you vomit after taking a dose of RYDAPT, do not take an extra dose. Take your next dose at your scheduled time

WHAT ARE THE POSSIBLE SIDE EFFECTS OF RYDAPT?

RYDAPT may cause serious side effects, including:

• Lung problems. RYDAPT may cause lung problems that may lead to death when used alone or in combination with other chemotherapy medicines. Get medical help right away if you have any new or worsening lung symptoms, including cough, chest discomfort, or shortness of breath

Click here for full Prescribing Information for RYDAPT.

Approved Uses and Important Safety Information (cont'd)

The most common side effects of RYDAPT[®] (midostaurin) capsules in people with AML include:

- low white blood cell counts with fever (febrile neutropenia)
- nausea
- redness, pain, or ulcers on the inside of your mouth (mucositis)
- vomiting
- headache

- bruising
- muscle or bone pain
- nose bleeds
- device-related infection
- high blood sugar levels (hyperglycemia)
- upper respiratory tract infection
- abnormal electrocardiogram (QT prolongation)

The most common side effects of RYDAPT in people with ASM, SM-AHN, or MCL include:

- nausea
- vomiting
- diarrhea
- swelling of your hands, feet, or ankles
- muscle or bone pain
- stomach-area pain

- tiredness
- upper respiratory tract infection
- constipation
- fever
- headache
- trouble breathing

Call or inform your health care provider if nausea, vomiting, or diarrhea occurs, gets worse, or does not go away.

RYDAPT may cause fertility problems in females and males, which may affect your ability to have children. Talk to your health care provider if you have concerns about fertility.

Your health care provider may tell you to decrease your dose, temporarily stop, or completely stop taking RYDAPT if you develop certain side effects during treatment with RYDAPT.

Your health care provider will do blood tests to check you for side effects during treatment with RYDAPT.

These are not all of the possible side effects of RYDAPT. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

<u>Click here</u> for full Prescribing Information for RYDAPT.



Approved Uses and Important Safety Information (cont'd)

HOW SHOULD I STORE RYDAPT?

- Store RYDAPT[®] (midostaurin) capsules at room temperature between 68°F to 77°F (20°C to 25°C)
- Keep RYDAPT in the original package to protect from moisture

Keep RYDAPT and all medicines out of the reach of children.

GENERAL INFORMATION ABOUT THE SAFE AND EFFECTIVE USE OF RYDAPT

Medicines are sometimes prescribed for conditions not listed in the Patient Information. Do not take RYDAPT for a condition for which it was not prescribed. Do not give RYDAPT to other people, even if they have the same condition or symptoms you have. It may harm them. You can ask your pharmacist or health care provider for information about RYDAPT that is written for health care professionals.

WHAT ARE THE INGREDIENTS IN RYDAPT?

Active ingredient: midostaurin.

Inactive ingredients: carmine, corn oil mono-di-triglycerides, dehydrated alcohol, ferric oxide red, ferric oxide yellow, gelatin, glycerin 85%, hypromellose 2910, polyethylene glycol 400, polyoxyl 40 hydrogenated castor oil, propylene glycol, purified water, titanium dioxide, and vitamin E.

Click here for full Prescribing Information for RYDAPT.

FINANCIAL SUPPORT

Novartis Oncology Universal Co-pay Program

You may be eligible for immediate co-pay savings on your next prescription of RYDAPT® (midostaurin) capsules.

Commercially insured patients have no co-pay charge*
Novartis will pay the remaining co-pay, up to \$15,000 per calendar year

*Limitations apply. This offer is only available to patients with private insurance. The program is not available for patients that are enrolled in Medicare, Medicaid, or any other federal or state health care program. Novartis reserves the right to rescind, revoke, or amend this program without notice. For full Terms and Conditions, visit www.Copay.NovartisOncology.com or call 1-877-577-7756.

To find out if you are eligible for the Novartis Oncology Universal Co-pay Program, call **1-877-577-7756** or visit **www.Copay.NovartisOncology.com**.

Terms and Conditions: The Novartis Oncology Universal Co-pay Program includes the co-pay card, payment card, or rebate with a combined annual limit of \$15,000. Patient is responsible for any costs once the limit is reached in a calendar year. This offer is only available to patients with private insurance. The program is not available for patients who: (i) are enrolled in Medicare, Medicaid, TRICARE, VA, DoD, or any other federal or state health care program; (ii) are not using insurance coverage at all; (iii) are enrolled in an insurance plan that reimburses for the entire cost of the drug; or (iv) where product is not covered by patient's insurance. The value of this program is exclusively for the benefit of enrolled patients and is intended to be credited toward patient out-of-pocket obligations, including applicable co-payments, coinsurance, and deductibles. Proof of purchase may be required. Patient may not seek reimbursement for the value received from this program from other parties, including any health insurance program or plan, flexible spending account, or health care savings account. Patient is responsible for complying with any applicable limitations and requirements of his/her health plan related to the use of the program. Program is not valid where prohibited by law. Valid only in the United States and Puerto Rico. Offer is not valid for California or Massachusetts residents for certain medications. This program is not health insurance. This program may not be combined with any third-party rebate, coupon, or offer. Novartis reserves the right to rescind, revoke, or amend the program and discontinue support at any time without notice.

Patient Instructions: After enrollment in the program, present this card and your insurance card along with a valid prescription at any participating pharmacy or through mail order. Patients are responsible for up to the first \$25 (specific offer varies by brand) and Novartis pays up to \$15,000 per calendar year. If patient reaches the maximum annual cap per calendar year of \$15,000, patient will be responsible for the difference.


When you use this card, you are certifying that you understand and agree to comply with the program Terms and Conditions above.

Direct patient questions to: 1-877-577-7756.

Please see Important Safety Information on the previous pages. <u>Click here</u> for full Prescribing Information for RYDAPT.











Please see Important Safety Information on the previous pages. <u>Click here</u> for full Prescribing Information for RYDAPT.



Novartis Pharmaceuticals Corporation East Hanover, New Jersey 07936-1080